Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
TipRanksMar 6 06:40 ET
SpringWorks Therapeutics Analyst Ratings
BenzingaMar 6 06:37 ET
Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Springworks Therapeutics (SWTX)
TipRanksFeb 29 06:30 ET
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)
TipRanksFeb 28 05:50 ET
Springworks Therapeutics: A Buy Rating on Ogsiveo's Success and Promising Pipeline
TipRanksFeb 28 05:50 ET
SpringWorks Therapeutics Analyst Ratings
BenzingaFeb 26 09:42 ET
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
TipRanksFeb 26 08:00 ET
Goldman Sachs Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
TipRanksFeb 26 06:19 ET
SpringWorks Therapeutics Analyst Ratings
BenzingaJan 25 09:56 ET
Analyst Ratings for SpringWorks Therapeutics
BenzingaNov 29, 2023 08:00 ET
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $73
BenzingaNov 29, 2023 06:50 ET
Buy Rating on Springworks Therapeutics With Increased Price Target Following FDA Approval of Ogsiveo
TipRanksNov 28, 2023 19:07 ET
Analysts' Top Healthcare Picks: Avidity Biosciences (RNA), Springworks Therapeutics (SWTX)
TipRanksNov 28, 2023 13:50 ET
Buy Rating Affirmed for Springworks Therapeutics on OGSIVEO's Superior Efficacy and FDA Approval
TipRanksNov 28, 2023 09:45 ET
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $64
BenzingaNov 28, 2023 09:33 ET
SpringWorks Therapeutics Analyst Ratings
BenzingaNov 28, 2023 09:32 ET
Buy Rating for Springworks Therapeutics on Strong FDA Approval and Market Potential
TipRanksNov 27, 2023 18:25 ET
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $52
BenzingaNov 20, 2023 06:22 ET
SpringWorks Therapeutics Analyst Ratings
BenzingaNov 20, 2023 06:20 ET
Springworks Therapeutics Receives Buy Rating Based on Promising Mirdametinib Drug Efficacy and Potential Market Dominance
TipRanksNov 17, 2023 05:45 ET
No Data
No Data